ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company's wholly owned step down subsidiary Orit Laboratories LLC has received US Food & Drug Administration (USFDA) Approval for Fenofibrate Tablets USP, 54 mg and 160 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Alembic Pharmaceuticals Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate. Alembic Pharmaceuticals Ltd - 533573 - Alembic Pharmaceuticals Limited Announces Completion Of USFDA Inspection At Aleor Dermaceuticals Limited.
With reference to the captioned subject, this is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd. (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has completed United States Food and Drug Administration (USFDA) inspection at its formulation manufacturing facility located at Karakhadi, Gujarat, India; with two observations. The inspection was carried out from 4th February, 2019 to 8th February, 2019. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of advertisement related to notice of loss of share certificates published by the Company on behalf of the shareholder(s) and / or legal heir(s) of the registered shareholder(s) in English language newspaper - Business Standard on 5th February, 2019. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Alembic Pharmaceuticals Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate. Alembic Pharmaceuticals Ltd - 533573 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Alembic Pharmaceuticals Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate. Alembic Pharma sees steady business from opportunities in India
Looks to capitalise on spot opportunities in the US and Europe Alembic Pharma Q3 profit up 30% to 170 cr
Alembic Pharmaceuticals on Tuesday reported 30 per cent rise in consolidated net profit to 169.83 crore for the quarter ended December 31, 2018 main Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Resignation of Director
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform the exchange that Mr. Milin Mehta has resigned as Independent Director of the Company w.e.f. end of day 22nd January, 2019. We enclose herewith a copy of the resignation letter submitted by Mr. Milin Mehta to the Board of the Company. Mr. Chirayu Amin, Chairman & CEO of the Company, commenting on his resignation said 'Mr. Milin Mehta is a well respected professional and provided invaluable contribution during his association with the Company as Independent Director. I wish him all the best.' Mr. Paresh Saraiya, Chairman of Audit Committee of the Company, commenting on his resignation said 'Mr. Milin Mehta, as a colleague in the Audit Committee as well as on the Board was a great asset and we have gained immensely from his expertise and inputs. I thank Mr. Milin Mehta for all his contributions to the Company.' We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Outcome of Board Meeting
With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has approved the Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2018. We enclose herewith the following: a) Consolidated Unaudited Financial Results for the quarter and nine months period ended on 31st December, 2018. b) Standalone Unaudited Financial Results for the quarter and nine months period ended 31st December, 2018. c) Limited Review Report by Statutory Auditors on Consolidated as well as on Standalone Unaudited Financial Results. d) Press Release. e) Investor Presentation. The time of commencement of the Board Meeting was 12:00 noon and the time of conclusion was 1:30 p.m. We request you to kindly take the same on record.